October 13th, 2014
Selections from Richard Lehman’s Literature Review: October 13th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include a comparison of once-weekly dulaglutide and once-daily liraglutide in metformin-treated patients with type 2 diabetes and variation in patients’ perceptions of elective PCI in stable CAD.
September 18th, 2014
FDA Approves New Once-Weekly GLP-1 Receptor Agonist for Type 2 Diabetes
Larry Husten, PHD
The FDA said today that it had approved dulaglutide, Lilly’s once-weekly injection to control blood sugar in adults with type 2 diabetes. The drug will be marketed under the brand name of Trulicity. The FDA said that the safety and efficacy of dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, had been studied in 3,342 type 2 diabetics. The drug […]
NEJM Journal Watch — Recent Cardiology Articles- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise
- Aprocitentan, a Newly Approved Drug for Resistant Hypertension
- Preventive PCI of Vulnerable Plaques Linked to Fewer Cardiac Events
- News from the ACC Scientific Session 2024